Ensysce Biosciences, Inc. (ENSC) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.19
↓-95% vs avg
5yr avg: 4.21
30Y Low4.2·High4.2
ROE
-585.4%
+0% vs avg
5yr avg: -585.4%
30Y Low-11%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ENSC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ensysce Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $14M | $36M | $24M | $1.4B | $285.1B | $228.5B | $212.3B | — |
| Enterprise Value | $-2023420 | $11M | $36M | $26M | $1.4B | $285.1B | $228.5B | $212.3B | — |
| P/E Ratio → | -0.08 | — | — | — | — | 79937.36 | 156300.00 | — | — |
| P/S Ratio | 0.23 | 2.73 | 16.14 | 9.63 | 402.58 | 72512.81 | 129529.84 | — | — |
| P/B Ratio | 0.19 | 4.21 | — | — | — | — | — | 1075.65 | — |
| P/FCF | — | — | — | — | — | — | 20781.07 | — | — |
| P/OCF | — | — | — | — | — | — | 20781.08 | — | — |
P/E links to full P/E history page with 30-year chart
ENSC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.12 | 16.01 | 10.14 | 403.98 | 72513.85 | 129531.14 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | 79343.22 | — |
| EV / EBIT | — | — | — | — | — | 341553.15 | — | 79343.22 | — |
| EV / FCF | — | — | — | — | — | — | 20781.28 | — | — |
ENSC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Ensysce Biosciences, Inc. earns an operating margin of -129.2%. Operating margins have expanded from -959.9% to -129.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -585.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -38.6% | -38.6% | -240.1% | -686.1% | 100.0% | 100.0% | -92.9% | — | — |
| Operating Margin | -129.2% | -129.2% | -480.4% | -959.9% | -562.7% | -41.0% | -485.7% | — | — |
| Net Profit Margin | -153.3% | -153.3% | -475.7% | -957.9% | -823.6% | 1.4% | -572.7% | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -585.4% | -585.4% | — | — | — | — | -10.6% | -0.7% | -0.0% |
| ROA | -192.3% | -192.3% | -247.0% | -216.8% | -346.9% | 11.6% | -9.8% | -0.7% | -0.0% |
| ROIC | — | — | — | — | — | — | -6.7% | -0.4% | -0.1% |
| ROCE | -486.8% | -486.8% | — | — | — | — | -8.7% | -0.5% | -0.1% |
ENSC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $301660, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.95 | — | — | — | — | — | -0.01 | -0.01 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -0.62 | — |
| Debt / FCF | — | — | — | — | — | — | 0.21 | — | — |
| Interest Coverage | -5.22 | -5.22 | -30.28 | -221.16 | -15.34 | -1.62 | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($301660)
ENSC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Ensysce Biosciences, Inc.'s current ratio of 2.42x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.56x to 2.42x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.42 | 2.42 | 0.69 | 0.56 | 0.95 | 0.05 | 0.08 | 4.38 | 14.77 |
| Quick Ratio | 2.42 | 2.42 | 0.69 | 0.56 | 0.98 | 0.05 | 0.08 | 4.38 | 14.77 |
| Cash Ratio | 1.59 | 1.59 | 0.34 | 0.33 | 0.74 | 0.03 | 0.05 | 3.79 | 13.38 |
| Asset Turnover | — | 0.93 | 0.82 | 0.43 | 0.22 | 11.17 | 2.83 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 8.70 | 15.96 | 40.04 | 45.66 | — | 35.91 | — | — |
ENSC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ensysce Biosciences, Inc. returns 100.0% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 100.0% | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.0% | 0.0% | — | — |
| FCF Yield | — | — | — | — | — | — | 0.0% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $2M | $2M | $179932 | $84018 | $6M | $6M | $6M | $6M |
Peer Comparison
Compare ENSC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ENSCYou | $1M | -0.1 | — | — | -38.6% | -129.2% | -585.4% | — | — |
 COLL | $1B | 22.7 | 4.8 | 3.9 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 ATAI | $964M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CMPS | $902M | -3.0 | — | — | — | — | -565.3% | — | — |
 SNDL | $376M | -33.0 | 7.9 | 8.8 | 27.3% | -0.5% | -1.4% | -0.3% | 3.3 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See ENSC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ENSC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ENSC vs COLL
Side-by-side business, growth, and profitability comparison vs Collegium Pharmaceutical, Inc..
Start ComparisonENSC — Frequently Asked Questions
Quick answers to the most common questions about buying ENSC stock.
What is Ensysce Biosciences, Inc.'s P/E ratio?
Ensysce Biosciences, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Ensysce Biosciences, Inc.'s ROE?
Ensysce Biosciences, Inc.'s return on equity (ROE) is -585.4%. The historical average is -3.8%.
Is ENSC stock overvalued?
Based on historical data, Ensysce Biosciences, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Ensysce Biosciences, Inc.'s dividend yield?
Ensysce Biosciences, Inc.'s current dividend yield is 100.00%.
What are Ensysce Biosciences, Inc.'s profit margins?
Ensysce Biosciences, Inc. has -38.6% gross margin and -129.2% operating margin.